MPO and myeloproliferative disorder: Massarenti et al. studied the effect of PEG-IFNα treatment on the serum levels of MPO-DNA complexes, a marker of NET formation, in patients with MPN enrolled on a clinical trial comparing PEG-IFNα therapy to hydroxyurea.